title: The pharmacokinetics of dilevalol in renal impairment.
abstract: Dilevalol, 200 mg, was administered orally as seven daily doses to three groups of six participants, with differing degrees of renal impairment. Values of Cmax, Tmax, half-life or renal elimination did not significantly change with decreased renal function. Values of area under the plasma concentration-time curves and pre-dose concentrations tended to increase with renal impairment and there was a significant, if small, correlation between these and glomerular filtration rate. The practical clinical consequences of these results is that impairment is not likely to be associated with significant accumulation of dilevalol.
authors.affiliation: Institute of Biopharmaceuticals, Athlone, Ireland.
authors.forename: J G
authors.initials: JG
authors.lastname: Kelly
authors.forename: M S
authors.initials: MS
authors.lastname: Laher
authors.forename: J
authors.initials: J
authors.lastname: Donohue
authors.forename: G D
authors.initials: GD
authors.lastname: Doyle
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005260:Female; D005919:Glomerular Filtration Rate; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D007741:Labetalol / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012016:Reference Values
chemical_list: D007741:Labetalol